Literature DB >> 19318907

Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging.

Michelle Floris-Moore1, Zahi A Fayad, Joan W Berman, Venkatesh Mani, Ellie E Schoenbaum, Robert S Klein, Karen B Weinshelbaum, Valentin Fuster, Andrea A Howard, Yungtai Lo, Alison D Schecter.   

Abstract

BACKGROUND: HIV-infected individuals may be at increased risk for atherosclerosis. Although this is partially attributable to metabolic factors, HIV-associated inflammation may play a role.
OBJECTIVE: To investigate associations of HIV disease with serum monocyte chemoattractant protein-1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2) levels and atherosclerosis burden.
DESIGN: A cross-sectional analysis.
METHODS: : Serum MCP-1/CCL2, fasting lipids, and glucose tolerance were measured in 98 HIV-infected and 79 demographically similar uninfected adults. Eighty-four participants had MRI of the carotid arteries and thoracic aorta to measure atherosclerosis burden. Multivariate analyses were performed using linear regression.
RESULTS: Mean MCP-1/CCL2 levels did not differ between HIV-infected and uninfected participants (P = 0.65). Among HIV-infected participants, after adjusting for age, BMI, and cigarette smoking, HIV-1 viral load was positively associated with MCP-1/CCL2 (P = 0.02). Multivariate analyses adjusting for sex, low-density lipoprotein cholesterol, total cholesterol:high-density lipoprotein cholesterol ratio, cigarette smoking, MCP-1/CCL2, and protease inhibitor use found that HIV infection was associated with greater mean thoracic aorta vessel wall area (VWA, P < 0.01) and vessel wall thickness (VWT, P = 0.03), but not with carotid artery parameters. Compared with being uninfected, having detectable HIV-1 viremia was associated with greater mean thoracic aorta VWA (P < 0.01) and VWT (P = 0.03), whereas being HIV-infected with undetectable viral load was associated with greater thoracic aorta VWA (P = 0.02) but not VWT (P = 0.15). There was an independent positive association of MCP-1/CCL2 with thoracic aorta VWA (P = 0.01) and VWT (P = 0.01).
CONCLUSION: HIV-1 viral burden is associated with higher serum levels of MCP-1/CCL2 and with atherosclerosis burden, as assessed by thoracic aorta VWA and VWT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318907      PMCID: PMC2786203          DOI: 10.1097/QAD.0b013e328329c76b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

1.  Exposure to fluid shear stress modulates the ability of endothelial cells to recruit neutrophils in response to tumor necrosis factor-alpha: a basis for local variations in vascular sensitivity to inflammation.

Authors:  Sajila Sheikh; G Ed Rainger; Zoe Gale; Mahbub Rahman; Gerard B Nash
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

2.  Surgical experience with carotid stenosis in young HIV-1 positive patients under antiretroviral therapy: an emerging problem?

Authors:  G Regina; G Impedovo; D Angiletta; F Martiradonna; A Lillo; F Perilli; V Marotta; A Marzullo; G Epifani; J R Fiore; P Maggi
Journal:  Eur J Vasc Endovasc Surg       Date:  2005-02       Impact factor: 7.069

3.  Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction.

Authors:  Arnon Blum; Vered Hadas; Michael Burke; Israel Yust; Ada Kessler
Journal:  Clin Cardiol       Date:  2005-03       Impact factor: 2.882

4.  Human vascular smooth muscle cells possess functional CCR5.

Authors:  A D Schecter; T M Calderon; A B Berman; C M McManus; J T Fallon; M Rossikhina; W Zhao; G Christ; J W Berman; M B Taubman
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

5.  Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study.

Authors:  Farouc A Jaffer; Christopher J O'Donnell; Martin G Larson; Stephen K Chan; Kraig V Kissinger; Michelle J Kupka; Carol Salton; Rene M Botnar; Daniel Levy; Warren J Manning
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-05-01       Impact factor: 8.311

6.  Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.

Authors:  J H Stein; M A Klein; J L Bellehumeur; P E McBride; D A Wiebe; J D Otvos; J M Sosman
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

7.  Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1alpha and RANTES correlate with virus load in human immunodeficiency virus infection.

Authors:  L Weiss; A Si-Mohamed; P Giral; P Castiel; A Ledur; C Blondin; M D Kazatchkine; N Haeffner-Cavaillon
Journal:  J Infect Dis       Date:  1997-12       Impact factor: 5.226

Review 8.  Endothelial dysfunction, hemodynamic forces, and atherogenesis.

Authors:  M A Gimbrone; J N Topper; T Nagel; K R Anderson; G Garcia-Cardeña
Journal:  Ann N Y Acad Sci       Date:  2000-05       Impact factor: 5.691

9.  Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients.

Authors:  A Tabib; C Leroux; J F Mornex; R Loire
Journal:  Coron Artery Dis       Date:  2000-02       Impact factor: 1.439

10.  Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.

Authors:  Priscilla Y Hsue; Joan C Lo; Arlana Franklin; Ann F Bolger; Jeffrey N Martin; Steven G Deeks; David D Waters
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

View more
  17 in total

1.  Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection.

Authors:  Rebeccah A McKibben; Joseph B Margolick; Steven Grinspoon; Xiuhong Li; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Richard T George; Lisa P Jacobson; Matthew Budoff; Russell P Tracy; Todd T Brown; Wendy S Post
Journal:  J Infect Dis       Date:  2014-10-30       Impact factor: 5.226

Review 2.  HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease.

Authors:  Revery P Barnes; John Charles A Lacson; Hossein Bahrami
Journal:  Curr Atheroscler Rep       Date:  2017-05       Impact factor: 5.113

3.  Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy.

Authors:  Chris T Longenecker; Ying Jiang; Chun-Ho Yun; Sara Debanne; Nicholas T Funderburg; Michael M Lederman; Norma Storer; Danielle E Labbato; Hiram G Bezerra; Grace A McComsey
Journal:  Int J Cardiol       Date:  2013-07-22       Impact factor: 4.164

4.  A genome-wide association study of carotid atherosclerosis in HIV-infected men.

Authors:  Sadeep Shrestha; Marguerite R Irvin; Kent D Taylor; Howard W Wiener; Nicholas M Pajewski; Talin Haritunians; Joseph A C Delaney; Morris Schambelan; Joseph F Polak; Donna K Arnett; Yii-Der Ida Chen; Carl Grunfeld
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

5.  Atherosclerosis is Evident in Treated HIV-Infected Subjects With Low Cardiovascular Risk by Carotid Cardiovascular Magnetic Resonance.

Authors:  Kathleen A M Rose; Jaime H Vera; Peter Drivas; Winston Banya; Niall Keenan; Dudley J Pennell; Alan Winston
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

6.  Non-classical monocytes predict progression of carotid artery bifurcation intima-media thickness in HIV-infected individuals on stable antiretroviral therapy.

Authors:  Dominic C Chow; Jamie M Kagihara; Guangxiang Zhang; Scott A Souza; Howard N Hodis; Yanjie Li; Brooks I Mitchell; Beau K Nakamoto; Kalpana J Kallianpur; Sheila M Keating; Philip J Norris; Lindsay B Kohorn; Lishomwa C Ndhlovu; Cecilia M Shikuma
Journal:  HIV Clin Trials       Date:  2016-04-04

7.  Plasma monocyte chemoattractant protein-1 and tumor necrosis factor-α levels predict the presence of coronary artery calcium in HIV-infected individuals independent of traditional cardiovascular risk factors.

Authors:  Cecilia M Shikuma; Jason D Barbour; Lishomwa C Ndhlovu; Sheila M Keating; Philip J Norris; Matthew Budoff; Nisha Parikh; Todd Seto; Louie Mar A Gangcuangco; Debra Ogata-Arakaki; Dominic Chow
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09-21       Impact factor: 2.205

8.  Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment.

Authors:  Robert C Kaplan; Alan L Landay; Howard N Hodis; Stephen J Gange; Philip J Norris; Mary Young; Kathryn Anastos; Phyllis C Tien; Xiaonan Xue; Jason Lazar; Christina M Parrinello; Lorie Benning; Russell P Tracy
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-01       Impact factor: 3.731

9.  The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.

Authors:  Gerard Aragonès; Pedro Pardo-Reche; Laura Fernández-Sender; Anna Rull; Raúl Beltrán-Debón; Esther Rodríguez-Gallego; Jordi Camps; Jorge Joven; Carlos Alonso-Villaverde
Journal:  Mediators Inflamm       Date:  2012-05-07       Impact factor: 4.711

Review 10.  HIV infection and stroke: current perspectives and future directions.

Authors:  Laura A Benjamin; Alan Bryer; Hedley C A Emsley; Saye Khoo; Tom Solomon; Myles D Connor
Journal:  Lancet Neurol       Date:  2012-10       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.